Treatment of Rheumatoid Arthritis with Unani Medicine and its relation with genes

Study of gene expression and gene polymorphism in pathogenesis of Rheumatoid Arthritis and their relationship with Unani Philosophy in Indian population

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/053034

Enrollment

Registered

2023-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified

Interventions

Intervention1: UNIM 301 and UNIM 304: UNIM 301 to be given 2 tabs (500 mg each) BD orally and UNIM 304 for external application twice daily for 4 months Control Intervention1: Not applicable : Compare

Eligibility

Inclusion criteria

Inclusion criteria: The patients diagnosed with Rheumatoid Arthritis (RA). Aged between 25-60 years. (Sero positive patients will only be included) for controls : Subjects without Diabetes, Hypertension, Age and Gender matched to patients.

Exclusion criteria

Exclusion criteria: The Subjects who are unwilling to give the blood sample. Pregnant women, lactating women, cancers patients and mentally disorder people

Design outcomes

Primary

Measure	Time frame
Improvement in ACR, CRP and RF in cases of Rheumatoid arthritisTimepoint: 1, 2, 3, 4 month	—

Secondary

Measure	Time frame
Gene polymorphism studies in the current study will give us severity levels of RA disease in a particular gene which will helps in therapeutic approach for further studies.Timepoint: 4 months;study will provide an understanding about the cellular and molecular mechanism of regimes being used for treatment of RA from centuries.Timepoint: 4 months;The present research on expression of MiR â?? 146a/b, TNFÎ± and IL- 1Î² would shed light on identifying potential biomarkers for therapeutic approaches in R A in relation to clinical phenotyping and Unani regime and help in understanding their role in Pathogenesis.Timepoint: 4 months	—

Measure

Time frame

Gene polymorphism studies in the current study will give us severity levels of RA disease in a particular gene which will helps in therapeutic approach for further studies.Timepoint: 4 months;study will provide an understanding about the cellular and molecular mechanism of regimes being used for treatment of RA from centuries.Timepoint: 4 months;The present research on expression of MiR â?? 146a/b, TNFÎ± and IL- 1Î² would shed light on identifying potential biomarkers for therapeutic approaches in R A in relation to clinical phenotyping and Unani regime and help in understanding their role in Pathogenesis.Timepoint: 4 months

—

Countries

India

Contacts

Public ContactDr Ahmed Minhajuddin

National Research Institute of Unani Medicine for Skin Disorders

dranwar_ahmed@yahoo.com9440417005

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026